Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
The expiration date of the key patent for guselkumab?Can lipitor's dosage change cause liver enzyme fluctuations?Motegrity ingredients?Drugpatentwatch trametinib?Guselkumab brand name?
See the DrugPatentWatch profile for aranesp
Aranesp (darbepoetin alfa) treats anemia by stimulating red blood cell production. It mimics erythropoietin, a hormone from the kidneys that signals bone marrow to make more red blood cells.[1]
Aranesp binds to erythropoietin receptors on bone marrow cells, promoting their growth and differentiation into red blood cells. This raises hemoglobin levels and reduces the need for blood transfusions in patients with chronic kidney disease or chemotherapy-induced anemia.[1][2]
Patients with hemoglobin below 10 g/dL due to kidney issues or chemo. It's injected under the skin or into a vein, often weekly or every other week.[1]
Pure red cell aplasia (rare bone marrow failure) has occurred, especially with certain formulations. Requires regular hemoglobin checks to avoid high levels, which raise heart attack or stroke risk. Not for use in cancer without anemia symptoms.[1][2]
Other Questions About Aranesp :